-
J.P. Morgan Increases PT On ALKS To $21
Thursday, May 19, 2011 - 9:02am | 118J.P. Morgan is raising the price target from $16 to $21 on Alkermes Inc. (NASDAQ: ALKS) in light of the company's F4Q result. According to J.P. Morgan, “We reiterate our OW on ALKS following its F4Q report after market close. In our view, ALKS is an increasingly well positioned company following...
-
Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
Thursday, May 19, 2011 - 8:38am | 54Families of Spinal Muscular Atrophy announced today that Repligen Corporation (Nasdaq: RGEN) has received approval from the U.S. Food and Drug Administration to commence a Phase I safety study in healthy volunteers for RG3039, formerly called Quinazoline495, which is being developed for Spinal...
-
Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting
Thursday, May 19, 2011 - 8:35am | 116Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from three studies of their investigational compound custirsen in castrate resistant prostate cancer will be presented at the 47th Annual Meeting of the American Society...
-
Piper Jaffray Reports On INFI As ASCO Abstracts Are Released
Thursday, May 19, 2011 - 8:02am | 126Piper Jaffray remains Overweight on Infinity Pharmaceuticals (NASDAQ: INFI) and maintains its $9 price target on the stock in advance of the company's presentation at ASCO in June. According to Piper Jaffray, “Abstracts were published last night for the upcoming American Society of Clinical...
-
UPDATE: Oppenheimer Raises PT on Incyte to $25 (INCY)
Thursday, May 19, 2011 - 7:58am | 162Oppenheimer is out with its report today on Incyte (NASDAQ: INCY), raising its PT from $25 to $23. In a note to clients, Oppenheimer writes, "We conducted a survey of 25 practicing oncologists regarding INCB18424's potential in myelofibrosis and polycythemia vera. The survey results support our...
-
Piper Jaffray Remains Neutral On ALNY In Advance Of ASCO Meeting
Thursday, May 19, 2011 - 7:57am | 92Piper Jaffray is maintaining its Neutral rating and its $10 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) as the company prepares to report at ASCO on June 4th. In the report, Piper Jaffray writes, “Abstracts were published last night for the upcoming American Society of Clinical Oncology...
-
Jefferies & Company Reports on Alkermes
Thursday, May 19, 2011 - 7:48am | 148In a report released today, Jefferies & Company commented on Alkermes (NASDAQ: ALKS). In the report, Jefferies was mixed in its assessment of the company. Jefferies writes, “Alkermes is making investments to build a long term, sustainably profitable company. The EDT acquisition diversifies the...
-
Morgan Stanley Reiterates Equal-Weight on Myriad Genetics
Thursday, May 19, 2011 - 7:47am | 179Morgan Stanley reiterated its Equal-weight rating on Myriad Genetics (NASDAQ: MYGN). In a research report published today, Morgan Stanley decided to leave its rating unchanged in spite of the company's ambition to expand into the European market in 2012. In the report, Morgan Stanley states, "...
-
JP Morgan Raises PT On Alkermes To $21
Thursday, May 19, 2011 - 7:33am | 26JP Morgan has raised the price target on Alkermes (NASDAQ: ALKS) from $16 to $21 and maintains its Overweight rating.
-
RXi Pharmaceuticals Presents Updated NeuVax Data At ASCO
Thursday, May 19, 2011 - 7:11am | 55RXi Pharmaceuticals Corporation (NASDAQ: RXII) developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual...
-
Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
Thursday, May 19, 2011 - 7:02am | 83Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 1 clinical study for ISIS-TTRRx. ISIS-TTRRx is designed to treat transthyretin amyloidosis, a severe and rare genetic disease...
-
Repligen Receives FDA Approval to Initiate Phase 1 Clinical Trial of Potential Treatment for Spinal Muscular Atrophy
Thursday, May 19, 2011 - 7:01am | 199Repligen Corporation (NASDAQ: RGEN) announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy (SMA). SMA is an inherited neurodegenerative disease in which a defect in the...
-
Metabolix Announces Commencement of Public Offering of 4.75M Shares
Wednesday, May 18, 2011 - 4:12pm | 117Metabolix, Inc. (NASDAQ: MBLX) today announced that it has commenced a public offering of shares of its common stock pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission. J.P. Morgan Securities LLC will serve as the sole book-...
-
Options Brief: Cytori Therapeutics (CYTX)
Wednesday, May 18, 2011 - 3:02pm | 91Shares of Cytori Therapeutics (NASDAQ: CYTX) are lower on the session by 3.45%, trading at $5.60. Overall call volume is now running at 3.68x the daily average, with 75% of all calls traded being purchases on the offer. 1,979 contracts have traded on the session so far. Cytori Therapeutics, Inc...
-
Biotech and Pharma News; BioSante Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences
Wednesday, May 18, 2011 - 11:44am | 341LINCOLNSHIRE, Ill. - May 18, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at two upcoming investors conferences on May 24, 2011. Stephen M. Simes, BioSante's president & CEO, will speak on May 24, 2011 at 11:00 am London time at the UBS...